Stephanie Gaillard, MD PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Astra-Zeneca
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Compugen
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    GOG/Clovis/Pharma&
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    NCTN
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    NRG
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Tempest
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other Securities
    Ineligible company:
    UpToDate
    Topic:
    Royalities
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Blueprint
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Immunogen
    Date added:
    08/21/2024
    Date updated:
    08/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    MDAnderson
    Date added:
    08/21/2024
    Date updated:
    08/21/2024

Pages

Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology